The epidermal growth factor receptor (Egfr) is a transmembrane receptor tryrosine kinase that is required in numerous tissues during development and is associated with many forms of cancer. From mouse knockout studies, the Egfr is known to be required for the maturation and/or maintenance of the mature intestinal tract. Furthermore, genetic evidence suggests that the Egfr is required during colorectal tumorigenesis. This is despite that fact that the gene encoding Egfr is not known to be mutated during colorectal cancer development. Although cancer of the colon and rectum is the third most frequently diagnosed cancer in the United States and accounts for the second largest number of cancer deaths, the role of only a few genes has been studied in detail; these genes are typically mutated during colorectal tumorigenesis or are associated with familial forms of the disease. Little is know about genes that appear to be required for the progression of tumorigenesis but do not become mutated themselves like Egfr. The objectives of the proposed research are therefore (1) to investigate the global importance of Egfr during development of colorectal cancer, (2) to determine the temporal requirement for Egfr during colorectal cancer development, (3) to define the mode of action of Egfr during tumorigenesis, and (4) to investigate the function of Egfr in non-epithelial compartments of the gastrointestinal tract.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA092479-01
Application #
6368720
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Freeman, Colette S
Project Start
2001-06-01
Project End
2006-05-31
Budget Start
2001-06-01
Budget End
2002-05-31
Support Year
1
Fiscal Year
2001
Total Cost
$271,314
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Genetics
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Scheving, Lawrence A; Zhang, Xiuqi; Threadgill, David W et al. (2016) Hepatocyte ERBB3 and EGFR are required for maximal CCl4-induced liver fibrosis. Am J Physiol Gastrointest Liver Physiol 311:G807-G816
Song, Xiaoling; Fan, Pang-Dian; Bantikassegn, Amlak et al. (2015) ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas. Cancer Res 75:1035-45
Scheving, Lawrence A; Zhang, Xiuqi; Stevenson, Mary C et al. (2015) Loss of hepatocyte ERBB3 but not EGFR impairs hepatocarcinogenesis. Am J Physiol Gastrointest Liver Physiol 309:G942-54
Scheving, Lawrence A; Zhang, Xiuqi; Stevenson, Mary C et al. (2015) Loss of hepatocyte EGFR has no effect alone but exacerbates carbon tetrachloride-induced liver injury and impairs regeneration in hepatocyte Met-deficient mice. Am J Physiol Gastrointest Liver Physiol 308:G364-77
Scheving, Lawrence A; Zhang, Xiuqi; Garcia, Oscar A et al. (2014) Epidermal growth factor receptor plays a role in the regulation of liver and plasma lipid levels in adult male mice. Am J Physiol Gastrointest Liver Physiol 306:G370-81
Franzke, Claus-Werner; Cobzaru, Cristina; Triantafyllopoulou, Antigoni et al. (2012) Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. J Exp Med 209:1105-19
Chen, Jianchun; Chen, Jian-Kang; Nagai, Kojiro et al. (2012) EGFR signaling promotes TGF?-dependent renal fibrosis. J Am Soc Nephrol 23:215-24
Eversley, Chevonne D; Yuying, Xie; Pearsall, R Scott et al. (2012) Mapping six new susceptibility to colon cancer (Scc) loci using a mouse interspecific backcross. G3 (Bethesda) 2:1577-84
Ardito, Christine M; GrĂ¼ner, Barbara M; Takeuchi, Kenneth K et al. (2012) EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22:304-17
Rinella, Erica S; Bankaitis, Eric D; Threadgill, David W (2012) Dietary calcium supplementation enhances efficacy but also toxicity of EGFR inhibitor therapy for colon cancer. Cancer Biol Ther 13:130-7

Showing the most recent 10 out of 24 publications